Clin Osteol 2025; 30(4): 216-220

Bone in the gynecology clinicReview articles

Tomáš Fait1, 2, Vlasta Dvořáková2
1 Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha
2 Katedra zdravotnických studií VŠPJ, Jihlava

The logical reason for linking gynecology with bone health care is the importance of estrogen for achieving optimal bone density and its dominant role in the prevention of postmenopausal osteoporosis. Bone health can thus be influenced by the choice of contraception, proper care for women with premature ovarian failure, rational choice of hormone replacement therapy during menopause, and early calcium and vitamin D supplementation in women at risk of osteoporosis. The role of gynecologists in bone health care has been confirmed by their current involvement in the screening and treatment of osteoporosis as primary care physicians.

Keywords: bone health, gynecologist, osteoporosis prevention, hormonal contraception, menopausal hormone therapy, bisphosphonates, denosumab.

Published: December 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T, Dvořáková V. Bone in the gynecology clinic. Clinical Osteology. 2025;30(4):216-220.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 1.12.2026

    References

    1. ČGPS ČLS JEP. Diagnostika a léčba postmenopauzální osteoporózy. Sbírka doporučených postupů č. 4/2022. Gyn Por. 2022;6(3):187-190.
    2. Lopez LM, Grimes DA, Schulz F, et al. Steroidal Contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2011;(7):CD006033.
    3. Fait T. Steroidní kontraceptiva - vliv na kostní metabolismus. Clin Osteol. 2024;29(4):8-13.
    4. Léčba a prevence nedostatku vitaminu D v oboru gynekologie a porodnictví. Sbírka doporučených postupů č. 9/2019. Gyn Por. 2023;7(4):245-248.
    5. Hronek M. Výživa ženy v období těhotenství a kojení. Praha: Maxdorf; 2004. 310 s.
    6. Gak N, Abbara A, Dhillo WS, et al. Current and future prospectives on pregnancy and lactation associated osteoporosis. Front Endocrinol (Lausanne). 2024;15:1494965.
    7. Rosa J. Prevence osteoporózy. In: Fait T, Vrablík M, Češka R, eds. Preventivní medicína. 4. vydání. 2021. s. 432.
    8. Hrstková H. Rizika a prevence osteoporózy u dětí. Pediatrie pro praxi. 2009;10(3):160-162.
    9. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.
    10. Robbins JA, Argaki A, Crandall CJ, et al. WHItrials: interaction of calcium and vitamin D with hormone therapy. Menopause. 2014;21(2):116-123.
    11. Torgerson DJ, Bell Syer SE. Hormone replacement therapy and prevention of non vertebral fracture: a meta analysis of randomized trials. JAMA. 2001;285(22):2891-2897.
    12. Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta analysis of randomized controlled trials. Menopause. 2016;23(4):461-470.
    13. Jiang X, Kagan R. Hormone therapy for osteoporosis management. Climacteric. 2022;25(1):50-55.
    14. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426-446.
    15. Kanis JA, McCloskey EV, Johansson H, et al. Casefinding for the management of osteoporosis with FRAX assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19(10):1395-1408.
    16. Lei S, Znang X, Song L, et al. Expert consensus on vitamin D in osteoporosis. Ann Jt. 2025;10:1.
    17. Rosa J, Šenk F, Palička V. Diagnostika a léčba postmenopauzální osteoporózy. Osteologický bulletin. 2015;4:150-168.
    18. Bayer M, Horák P, Palička V, et al. Dlouhodobá léčba osteoporózy denosumabem a její přerušení: odborné stanovisko pracovní skupiny SMOS ČLS JEP. Clin Osteol. 2018;23(1):32-37.
    19. Rosa J. Péče o pacientky s osteoporózou v klinické praxi. Gyn Por. 2024;8(1):2-8.
    20. Bayram F, Kilic SS, Aydin V, et al. Medication Related Osteonecrosis of the Jaw: Bibliometric Analysis from 2003 to 2023. Adv Exp Med Biol. 2025;1474:119-130.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.